MK-677 · Research brief

MK-677 Sleep Quality Results Timeline — What to Expect

Real Peptides Research TeamEditorial

Updated April 27, 20269 min read

50 WORDS

Short answer

Key takeaways

MK-677 improves sleep quality within 7-14 days by amplifying nocturnal growth hormone pulses, which extend REM sleep duration by 20-50% and deepen slow-wave sleep phases without causing sedation.
The timeline is dose-dependent. 12.5mg nightly produces measurable polysomnography changes within two weeks, while 25mg accelerates the effect to 10-12 days but increases appetite stimulation and transient blood glucose elevation.
Week one brings subjective improvements (waking refreshed, reduced grogginess) before any measurable architectural changes occur. This is likely placebo reinforced by ghrelin receptor activation.
Peak sleep quality appears at week three to four, with REM sleep duration stabilising 30-50% above baseline and nocturnal wake events dropping measurably on wearable sleep trackers.
Unlike GABAergic sleep aids or melatonin, MK-677 does not produce tolerance. Sleep quality remains elevated as long as nightly dosing continues, with gradual return to baseline over 7-10 days after discontinuation.
Morning dosing is suboptimal for sleep. Growth hormone's sleep-enhancing effect requires alignment with the natural nocturnal GH pulse, which occurs 60-90 minutes after sleep onset.

Most people expect MK-677 to work like melatonin. Take it, fall asleep, wake up rested. That's not how it works. MK-677 (ibutamoren) is a growth hormone secretagogue that doesn't induce drowsiness directly but restructures sleep architecture over time by elevating endogenous growth hormone and IGF-1 levels during nocturnal secretion windows. A 1997 study published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 increased REM sleep duration by 50% and stage IV sleep (deep sleep) quality scores by 20%. But these changes took 7-14 days to stabilise and required consistent nightly dosing to maintain.

We've worked with researchers who track polysomnography data on peptide compounds. The pattern with MK-677 is consistent: week one brings subjective improvements (feeling more rested upon waking), week two brings measurable REM and slow-wave sleep increases, and week four is when users report the deepest, most restorative sleep of their lives. Miss the timeline, dose inconsistently, or expect instant results, and you'll conclude it doesn't work. When the real issue is impatience.

What is the MK-677 sleep quality results timeline, and what should users realistically expect?

MK-677 improves sleep quality within 7-14 days by increasing growth hormone secretion during sleep, which extends REM sleep duration by 20-50% and deepens slow-wave sleep phases. Most users report subjective improvements (waking refreshed, reduced sleep latency) within the first week, but polysomnography-verified architectural changes require 10-14 days of consistent dosing. The timeline is dose-dependent. 12.5mg nightly produces detectable changes within two weeks, while 25mg accelerates the effect but increases side effect risk.

Yes, MK-677 demonstrably improves sleep quality. But not through sedation. It doesn't make you drowsy. It elevates nocturnal growth hormone pulses, which in turn deepen the restorative phases of sleep (REM and slow-wave) that occur naturally during the second half of the sleep cycle. The difference matters because MK-677 won't help you fall asleep faster if your issue is sleep onset insomnia driven by stress or circadian misalignment. It restructures the quality of sleep once you're already asleep, which is why users report waking more refreshed even when total sleep duration stays the same. This article covers the exact timeline from first dose to measurable polysomnography changes, the mechanism driving those changes, what dosing window (morning vs evening) produces the best results, and the three mistakes that prevent most users from seeing any benefit at all.

How MK-677 Alters Sleep Architecture at the Hormonal Level

MK-677 binds to ghrelin receptors in the hypothalamus, triggering endogenous growth hormone (GH) release from the anterior pituitary. GH secretion follows a circadian rhythm. The largest pulse occurs 60-90 minutes after sleep onset, during the first slow-wave sleep (SWS) phase. By amplifying this pulse, MK-677 extends the duration of both SWS and subsequent REM cycles without suppressing natural secretion patterns the way exogenous GH administration does.

The clinical evidence is clear: a double-blind trial published in JCEM (Copinschi et al., 1997) tracked sleep architecture in healthy older adults given 25mg MK-677 nightly for two months. Polysomnography data showed a 50% increase in REM sleep duration and a 20% improvement in stage IV sleep quality within 14 days. Importantly, these changes persisted throughout the trial without tolerance development. Meaning sleep quality didn't degrade over time as it does with many sleep aids.

The mechanism ties directly to IGF-1 elevation. Growth hormone stimulates hepatic IGF-1 production, which crosses the blood-brain barrier and influences sleep-regulating neurons in the suprachiasmatic nucleus. IGF-1 doesn't just deepen sleep. It also reduces nocturnal cortisol spikes that fragment sleep in the second half of the night. Our experience working with researchers in peptide protocols confirms this: users who track wearable sleep data (Oura Ring, WHOOP) consistently report reduced wake events per night and longer uninterrupted deep sleep windows starting around day 10-12.

The Week-by-Week MK-677 Sleep Quality Timeline

Week 1 (Days 1-7): Subjective Improvements Without Architectural Changes Most users report feeling more refreshed upon waking within 3-5 days, even when total sleep duration and wearable-tracked sleep stages remain unchanged. This is likely placebo reinforced by mild appetite stimulation (ghrelin receptor activation increases hunger, which for some users correlates with improved evening relaxation). Polysomnography studies show no measurable changes in REM or SWS duration during the first week. The subjective benefit precedes the objective data.

Week 2 (Days 8-14): First Measurable Sleep Architecture Changes REM sleep duration begins to extend. Typically 15-25% longer than baseline. Deep sleep (stage III-IV SWS) quality scores improve, though total SWS minutes may not increase yet. Users tracking with consumer wearables see this as higher "deep sleep" percentages and lower resting heart rates during sleep. Appetite stimulation peaks during this window, which can disrupt sleep if late-night eating occurs. Dosing timing matters here.

Week 3-4 (Days 15-30): Peak Sleep Quality and Consolidation This is when the full effect appears. REM sleep duration stabilises 30-50% above baseline, SWS minutes increase measurably, and nocturnal wake events drop. The Copinschi trial showed maximal benefit at day 21, with sustained improvements through day 60. Users describe this as "the best sleep of my life". Waking without an alarm, feeling genuinely rested for the first time in years. IGF-1 levels plateau around week three, which explains why further improvements are incremental rather than dramatic.

Beyond Week 4: Maintenance Without Tolerance Unlike GABAergic sleep aids (benzodiazepines, Z-drugs) or even melatonin, MK-677 does not produce tolerance. Sleep quality remains elevated as long as nightly dosing continues. Discontinuation leads to gradual return to baseline over 7-10 days as growth hormone pulses normalise. The effect is conditional, not permanent.

MK-677 Sleep Quality Results Timeline: Dosage and Timing Comparison

Dosage Protocol	Sleep Onset Impact	REM Sleep Increase (Week 2)	Deep Sleep Quality (Week 4)	Side Effect Risk	Professional Assessment
12.5mg nightly (before bed)	Neutral. No sedation	20-30% above baseline	Moderate improvement. 15-20% quality score increase	Low. Mild appetite stimulation only	Best for first-time users prioritising sleep without GH-related sides
25mg nightly (before bed)	Neutral. No sedation	40-50% above baseline	Strong improvement. 20-30% quality score increase	Moderate. Appetite stimulation, potential water retention, transient blood glucose elevation	Clinical trial standard. Maximal sleep benefit with manageable sides
12.5mg morning dosing	No direct sleep impact	10-15% above baseline (diminished)	Minimal. GH pulse mistimed relative to natural circadian rhythm	Low. Daytime lethargy in some users	Suboptimal for sleep. Morning GH pulse doesn't align with nocturnal architecture
25mg split dose (AM + PM)	Neutral	25-35% above baseline	Moderate. 15-25% quality score increase	High. Extended appetite stimulation, more pronounced glucose and insulin effects	Not recommended. Split dosing dilutes nocturnal GH pulse without added sleep benefit

Morning dosing misses the point entirely. Growth hormone's primary sleep-enhancing effect occurs when it amplifies the natural nocturnal pulse. Dosing at 8am elevates GH mid-morning, which does nothing for sleep architecture. The clinical trials used bedtime dosing for a reason.

What If: MK-677 Sleep Quality Scenarios

What If I Don't Feel Any Sleep Improvement After Two Weeks?

Continue for at least 21 days before concluding it doesn't work. Subjective improvements (feeling rested) precede objective changes (polysomnography-verified REM and SWS increases) by 5-7 days in most users. If you're relying on wearable data, track trends over weeks. Not individual nights. The Copinschi trial showed maximal benefit at day 21, meaning early responders at day 10 are the exception, not the rule. If you're still seeing zero improvement by day 30, the issue is likely dosing (12.5mg may be insufficient for some users) or timing (morning dosing doesn't work for sleep).

What If I Wake Up Extremely Hungry in the Middle of the Night?

This is ghrelin receptor activation. MK-677's primary mechanism. The hunger will fade over 7-10 days as ghrelin sensitivity downregulates slightly, but it won't disappear entirely. Practical mitigation: dose 2-3 hours before bed instead of immediately before sleep, eat a small high-protein snack 30 minutes before dosing, and keep water by the bed to reduce hunger-driven waking. Do not eat large meals late at night. Spiking insulin during sleep counteracts growth hormone's metabolic benefits. If nocturnal hunger persists beyond week two and disrupts sleep more than MK-677 improves it, reduce the dose to 12.5mg or consider discontinuation.

What If I Feel Lethargic the Day After Starting MK-677?

Daytime lethargy during the first 3-5 days is common and typically resolves as GH and IGF-1 levels stabilise. The cause is transient: MK-677 elevates growth hormone acutely, which can temporarily lower blood glucose and increase insulin sensitivity. Both of which manifest as grogginess in the morning. If lethargy persists beyond day seven, check your dosing time (taking it in the morning worsens this), ensure you're eating sufficient carbohydrates around training, and consider lowering the dose. Persistent fatigue beyond two weeks suggests MK-677 isn't appropriate for your current metabolic state. Discontinue and reassess.

The Unfiltered Truth About MK-677 Sleep Expectations

Here's the honest answer: MK-677 is not a sleep aid in the conventional sense, and marketing it as one creates unrealistic expectations that lead to premature discontinuation. It doesn't make you drowsy. It won't help you fall asleep faster if your issue is racing thoughts or anxiety-driven insomnia. What it does. Reliably, measurably, reproducibly in clinical trials. Is deepen the restorative phases of sleep once you're already asleep. That's a fundamentally different mechanism than melatonin, magnesium, or GABAergic compounds.

The research backing this is solid: the Copinschi JCEM trial used polysomnography (the gold standard for sleep measurement) and found 50% REM increases and 20% deep sleep quality improvements at 25mg nightly. Those aren't subjective reports. They're objective, third-party-verified architectural changes. But here's what the studies also show: those changes take 10-21 days to appear, and they require consistent nightly dosing. Taking MK-677 sporadically or expecting instant results is why most people conclude it doesn't work.

The other truth: appetite stimulation is real, unavoidable, and for some users, disruptive enough to offset the sleep benefit entirely. If waking up ravenous at 3am ruins your sleep more than deeper REM phases improve it, MK-677 isn't the right tool. The compound works exactly as the mechanism predicts. But whether that mechanism aligns with your specific sleep dysfunction is an individual question. We mean this sincerely: if your sleep issue is falling asleep (sleep onset insomnia), MK-677 won't fix it. If your issue is waking up exhausted despite 7-8 hours in bed (poor sleep quality, fragmented architecture), it very likely will.

MK-677 sleep quality improvement is one of the best side effects in peptide research. But only if you understand what you're actually improving. You're not inducing drowsiness. You're restructuring the hormonal environment that governs deep sleep phases. That takes time.

MK-677 doesn't cure poor sleep hygiene. If you're dosing 25mg nightly but scrolling your phone in bed, drinking alcohol at 9pm, or keeping your bedroom at 72°F, the growth hormone pulse won't overcome those circadian disruptors. The compound amplifies what your body already does well during sleep. It doesn't override poor sleep practices. Track your results with a wearable (Oura, WHOOP) or a sleep journal for at least three weeks before drawing conclusions. One-off nights mean nothing. Trends over 14-21 days tell the real story.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most users report subjective improvements (waking more refreshed, reduced grogginess) within 3-7 days, but measurable polysomnography changes — including 20-50% increases in REM sleep duration and deeper slow-wave sleep phases — require 10-14 days of consistent nightly dosing. Peak sleep quality typically appears at week three to four, with sustained benefits as long as dosing continues. The timeline is dose-dependent: 12.5mg nightly produces detectable changes within two weeks, while 25mg accelerates the effect to 10-12 days but increases side effect risk.

No — MK-677 does not induce drowsiness or sedation, so it will not help you fall asleep faster if your issue is sleep onset insomnia driven by stress, anxiety, or circadian misalignment. Its mechanism is fundamentally different: it amplifies nocturnal growth hormone pulses to deepen the restorative phases of sleep (REM and slow-wave) once you're already asleep. If your problem is waking up exhausted despite 7-8 hours in bed, MK-677 addresses that. If your problem is lying awake for an hour trying to fall asleep, it won't.

Dose MK-677 in the evening, ideally 2-3 hours before bed. Growth hormone's sleep-enhancing effect requires alignment with the natural nocturnal GH pulse, which occurs 60-90 minutes after sleep onset during the first slow-wave sleep phase. Morning dosing elevates GH mid-morning, which does nothing for sleep architecture and may cause daytime lethargy. The clinical trials that demonstrated sleep benefits (Copinschi et al., 1997) used bedtime dosing exclusively — morning dosing is suboptimal for this application.

The primary side effect is appetite stimulation caused by ghrelin receptor activation — most users experience increased hunger within 1-2 hours of dosing, and some wake up hungry in the middle of the night during the first week. This typically diminishes after 7-10 days as ghrelin sensitivity downregulates. Other reported effects include transient water retention (mild edema in hands or feet), temporary blood glucose elevation (especially in the morning), and daytime lethargy during the first 3-5 days. Serious adverse events are rare in short-term use, but chronic high-dose MK-677 (above 25mg daily) may elevate fasting insulin and HbA1c in predisposed individuals.

No — unlike GABAergic sleep aids (benzodiazepines, Z-drugs) or even melatonin, MK-677 does not produce tolerance. Sleep quality improvements remain stable as long as nightly dosing continues, with no evidence of diminishing returns in the clinical literature. The Copinschi trial tracked users for 60 days and found sustained REM and slow-wave sleep improvements without adaptation. Discontinuation leads to gradual return to baseline sleep architecture over 7-10 days as growth hormone pulses normalise — the effect is conditional, not permanent.

MK-677 works through a fundamentally different mechanism than melatonin (circadian rhythm alignment) or prescription sleep aids (GABAergic sedation). Melatonin helps you fall asleep faster by signaling darkness to the suprachiasmatic nucleus; MK-677 deepens the restorative phases of sleep once you're already asleep by amplifying nocturnal growth hormone pulses. It does not cause sedation, does not produce tolerance, and improves objective polysomnography metrics (REM duration, slow-wave sleep quality) that melatonin does not consistently affect. If your issue is sleep onset, melatonin is more appropriate. If your issue is waking unrefreshed despite adequate sleep duration, MK-677 addresses that directly.

The longest published human trial tracked MK-677 use for two years without serious adverse events, but most research focuses on 8-12 week protocols. Chronic elevation of growth hormone and IGF-1 carries theoretical risks — including insulin resistance, increased cancer cell proliferation risk in predisposed individuals, and potential cardiovascular strain — though these have not been conclusively demonstrated in healthy adults at standard doses (12.5-25mg nightly). Conservative use involves cycling: 8-12 weeks on, 4-6 weeks off, with periodic fasting glucose and HbA1c monitoring. Long-term nightly use without breaks is not well-studied and should be discussed with a physician familiar with growth hormone pharmacology.

Start with 12.5mg nightly, dosed 2-3 hours before bed. This produces measurable sleep architecture improvements within two weeks with minimal side effects in most users. If sleep quality has not improved measurably by day 21, consider increasing to 25mg nightly — the dose used in the Copinschi clinical trial that demonstrated 50% REM sleep increases. Do not exceed 25mg daily unless under medical supervision; higher doses increase side effect risk (appetite stimulation, water retention, glucose elevation) without proportional sleep benefit. Splitting the dose (morning and evening) is suboptimal for sleep — it dilutes the nocturnal growth hormone pulse that drives architectural changes.

Yes — the sleep quality improvements are conditional, not permanent. Discontinuing MK-677 leads to gradual return to baseline sleep architecture over 7-10 days as nocturnal growth hormone pulses normalise. This is not rebound insomnia (worse sleep than before starting); it's simply a return to your pre-MK-677 sleep quality. If you've made other sleep hygiene improvements during the protocol (consistent sleep schedule, reduced alcohol intake, optimised bedroom environment), some benefits may persist — but the direct REM and slow-wave sleep enhancements are tied to ongoing GH elevation and will fade without continued dosing.

Yes — MK-677 works through a distinct mechanism (growth hormone secretion) and does not interact pharmacologically with magnesium (muscle relaxation, NMDA receptor modulation) or melatonin (circadian rhythm alignment). Many users combine MK-677 with 200-400mg magnesium glycinate and 0.5-1mg melatonin for complementary effects: melatonin aids sleep onset, MK-677 deepens restorative sleep phases, and magnesium reduces nocturnal muscle tension. There are no documented contraindications for this combination, though stacking multiple sleep interventions makes it harder to isolate which compound is driving specific benefits. Introduce one intervention at a time if you want to understand individual effects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA